"Strengthening Medicines Regulatory Systems Abroad: Adapting Messages From Recent IOM Consensus Studies For Disease Control Priorities, Third Edition."
Hosted by the Institute of Medicine (IOM) of the National Academies, contributors to DCP3 convened in Washington, D.C. to discuss Volume 1, Chapter 11 of the nine volume series, entitled "Regulatory Strenthening."
The goal of this meeting was to use the following IOM reports as a starting point for developing a DCP3 chapter on medicines regulation. This chapter lays out the economic case for investing in drug regulation and models the financial consequence of neglecting it:
- "Ensuring Safe Foods and Medical Products through Stronger Regulatory Systems Abroad"
- "Countering the Problem of Falsified and Substandard Drugs"
- Presentation by Dr. Andy Stergachis
- Presentation by Dr. Adonis Bitegeko
- Presentation by David Lee-Chin
DCP3 and IOM contributors discuss opportunities for drug regulation in developing nations.
|Dr. Margaret Hamburg, Commissioner of the U.S. Food and Drug Administration, weighs in on the complexities of foreign drug regulation systems.